Novo Nordisk Investor Presentation - First Nine Months of 2016

Investor presentation First nine months of 2016 The GLP-1 segment accounts for around 3% of the total diabetes care market in International Operations International Operations GLP-1 market VictozaⓇ value market share in International Operations GLP-1 value in bDKK VictozaⓇ lixisenatide exenatide dulaglutide 0.8 0.7 CAGR value¹: 60.0% 0.6 0.5 0.4 0.3 0.2 0.1 0.0 Aug 2011 1 CAGR for 5-year period Source: IMS Monthly MAT August, 2016 value figures (DKK) changing diabetes® Share of total diabetes care market GLP-1 value market share 100% 5% 80% 4% 60% 3% 40% - 2% 20% 1% 0% 0% Aug Aug 2011 2016 Source: IMS Monthly MAT August, 2016 value figures (DKK) Slide 57 VictozaⓇ lixisenatide - exenatide - dulaglutide 81% Aug 2016 novo nordisk

View entire presentation